Evidence map›Paper›PMID 37601279›Full record

ArticlePediatric medicine (Hong Kong, China)2022

Mechanisms of Tertiary Neurodegeneration after Neonatal Hypoxic-Ischemic Brain Damage.

Steven W Levison, Eridan Rocha-Ferreira, Brian H Kim, Henrik Hagberg, Bobbi Fleiss, Pierre Gressens, Radek Dobrowolski

Open access · hybridAbstract read
In one paragraph

Article in Pediatric medicine (Hong Kong, China), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
5.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 5 countries.

Steven W LevisonDepartment of Pharmacology, Physiology, and Neuroscience, Rutgers University, New Jersey Medical School, Cancer Center, 205 South Orange Avenue, Newark, NJ 07103, USA.
Eridan Rocha-FerreiraCentre of Perinatal Medicine & Health, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Brian H KimDepartment of Pharmacology, Physiology, and Neuroscience, Rutgers University, New Jersey Medical School, Cancer Center, 205 South Orange Avenue, Newark, NJ 07103, USA.
Henrik HagbergCentre of Perinatal Medicine & Health, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Bobbi FleissCentre for the Developing Brain, Division of Imaging Sciences and Biomedical Engineering, King's College London, King's Health Partners, St. Thomas' Hospital, London, SE1 7EH, UK.
Pierre GressensCentre for the Developing Brain, Division of Imaging Sciences and Biomedical Engineering, King's College London, King's Health Partners, St. Thomas' Hospital, London, SE1 7EH, UK.
Radek DobrowolskiDepartment of Biology, Rutgers-Newark, Newark, NJ.
Rutgers, The State University of New Jersey · USUniversity of Gothenburg · SEInserm · FRKing's College London · GBRutgers New Jersey Medical School

Funding

Regulation of Neuronal Clearance Pathways via Nuclear Calcium Signaling in Alzheimer's DiseaseR01AG062475 · NIA · RUTGERS THE STATE UNIV OF NJ NEWARK · PI FRIEDMAN, WILMA J · 2019 to 2023
$2.3M
Intranasal LIF to improve neurological recovery from perinatal hypoxia-ischemaR01NS116828 · NINDS · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI LEVISON, STEVEN W · 2020 to 2024
$1.7M
Mucolipin-1-Mediated Mechanisms of Neuronal Clearance in Alzheimer’s DiseaseR56AG061040 · NIA · RUTGERS THE STATE UNIV OF NJ NEWARK · PI KIM, HAESUN A · 2019 to 2019
$385k
NIA NIH HHS R01 AG062475NIA NIH HHS R56 AG061040NINDS NIH HHS R01 NS116828
6 · The paper itself

Abstract

Neonatal encephalopathy linked to hypoxia-ischemia (H-I) which is regarded as the most important neurological problem of the newborn, can lead to a spectrum of adverse neurodevelopmental outcomes such as cerebral palsy, epilepsy, hyperactivity, cognitive impairment and learning difficulties. There have been numerous reviews that have focused on the epidemiology, diagnosis and treatment of neonatal H-I; however, a topic that is less often considered is the extent to which the injury might worsen over time, which is the focus of this review. Similarly, there have been numerous reviews that have focused on mechanisms that contribute to the acute or subacute injury; however, there is a tertiary phase of recovery that can be defined by cellular and molecular changes that occur many weeks and months after brain injury and this topic has not been the focus of any review for over a decade. Therefore, in this article we review both the clinical and pre-clinical data that show that tertiary neurodegeneration is a significant contributor to the final outcome, especially after mild to moderate injuries. We discuss the contributing roles of apoptosis, necroptosis, autophagy, protein homeostasis, inflammation, microgliosis and astrogliosis. We also review the limited number of studies that have shown that significant neuroprotection and preservation of neurological function can be achieved administering drugs during the period of tertiary neurodegeneration. As the tertiary phase of neurodegeneration is a stage when interventions are eminently feasible, it is our hope that this review will stimulate a new focus on this stage of recovery towards the goal of producing new treatment options for neonatal hypoxic-ischemic encephalopathy.

Indexed as

Brain InjuryCell Death MechanismsNeonate

Identifiers

PMID37601279
PMCPMC10438849
OpenAlexW3160318347

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.